Search details
1.
Two-stage stratified designs with survival outcomes and adjustment for misclassification in predictive biomarkers.
Stat Med
; 43(10): 1883-1904, 2024 May 10.
Article
in English
| MEDLINE | ID: mdl-38634277
2.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
N Engl J Med
; 383(15): 1425-1435, 2020 10 08.
Article
in English
| MEDLINE | ID: mdl-32966714
3.
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Diabetologia
; 64(6): 1256-1267, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33665685
4.
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Circulation
; 142(23): 2205-2215, 2020 12 08.
Article
in English
| MEDLINE | ID: mdl-33026243
5.
Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture.
Nutr Cancer
; 73(11-12): 2740-2750, 2021.
Article
in English
| MEDLINE | ID: mdl-33319628
6.
Two-stage enrichment clinical trial design with adjustment for misclassification in predictive biomarkers.
Stat Med
; 38(29): 5445-5469, 2019 12 20.
Article
in English
| MEDLINE | ID: mdl-31621944
7.
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Am Heart J
; 206: 11-23, 2018 12.
Article
in English
| MEDLINE | ID: mdl-30290289
8.
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
Diabetologia
; 65(5): 908-911, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35238955
9.
Methods of designing two-stage winner trials with survival outcomes.
Stat Med
; 33(9): 1539-63, 2014 Apr 30.
Article
in English
| MEDLINE | ID: mdl-24347247
10.
Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.
Int J Gynecol Cancer
; 24(9): 1636-41, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25304678
11.
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
Clin Cardiol
; 44(8): 1139-1143, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34129237
12.
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
BMJ Open Diabetes Res Care
; 9(1)2021 10.
Article
in English
| MEDLINE | ID: mdl-34620621
13.
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
JAMA Cardiol
; 6(2): 148-158, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-33031522
14.
The prevention and treatment of missing data in clinical trials.
N Engl J Med
; 367(14): 1355-60, 2012 Oct 04.
Article
in English
| MEDLINE | ID: mdl-23034025
15.
A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.
Clin Cancer Res
; 15(11): 3896-902, 2009 Jun 01.
Article
in English
| MEDLINE | ID: mdl-19458050
16.
Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis.
Ther Innov Regul Sci
; 54(5): 1236-1255, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32865809
17.
Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.
Cancer Cell
; 35(1): 64-80.e7, 2019 01 14.
Article
in English
| MEDLINE | ID: mdl-30612941
18.
Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design.
Stat Med
; 27(29): 6190-208, 2008 Dec 20.
Article
in English
| MEDLINE | ID: mdl-18800338
19.
Elicitation of a beta prior for Bayesian inference in clinical trials.
Biom J
; 50(2): 212-23, 2008 Apr.
Article
in English
| MEDLINE | ID: mdl-18085660
20.
A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.
Pigment Cell Melanoma Res
; 31(4): 534-540, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29453787